In particular, therapeutic antibodies that block the actions of TNFα, IL-1β, or IL-6 are very efficacious in downregulating inflammatory disease, but 30–50% of patients with RA are resistant to the antibodies [19]. The gene discussed is IL6; the disease is rheumatoid arthritis.